One of the most common treatments for cancer of the prostate that spreads beyond the prostate gland is androgen deprivation therapy (ADT). Prostate cancer is sensitive to testosterone and reducing testosterone levels in a man’s blood stream can slow the growth of prostate cancer and lower a man’s PSA level.
In the U.S. about 30% of men with prostate cancer will receive androgen deprivation therapy with injections of LHRH agonists and antagonists such Lupron, Zolodex, and Firmagon.
Men who did not have any history of cardiovascular disease who received (ADT) ahd an 81% increased risk for heart failure compared with men who did not receive ADT. For men who already had cardiovascular disease were also at a higher risk for heart disease especially rhythm disorders.
Bottom Line: Men with prostate cancer should have a discussion with their doctor whether ADT is a treatment that is appropriate especially if they have preexisting heart disease.